MIST Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.080

Open

1.030

VWAP

1.03

Vol

2.14M

Mkt Cap

118.84M

Low

1.000

Amount

2.21M

EV/EBITDA(TTM)

--

Total Shares

117.67M

EV

70.08M

EV/OCF(TTM)

--

P/S(TTM)

52.65

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Show More

Events Timeline

(ET)

2026-03-20

16:20:00

Major Averages Close Broadly Lower, S&P 500 Down Over 1.5%

2026-03-20

12:10:00

Major Averages Decline Again as Oil Prices Rise

2026-03-20

09:00:00

Stock Futures Modestly Lower, Market Sentiment Cautious

2026-03-20

07:20:00

Milestone Cash and Short-Term Investments Rise to $106M

2026-03-16 (ET)

2026-03-16

08:20:00

Milestone Pharmaceuticals to Showcase New Treatment at ACC 2026

2026-02-10 (ET)

2026-02-10

08:30:00

Milestone Appoints David Sandoval as General Counsel

2026-02-03 (ET)

2026-02-03

08:30:00

Milestone Pharmaceuticals Grants 419,000 Equity Awards

2026-01-26 (ET)

2026-01-26

08:10:00

Milestone Pharmaceuticals Launches Cardamyst Nasal Spray

2026-01-06 (ET)

2026-01-06

08:20:00

Milestone Pharmaceuticals Submits MAA for Etripamil Nasal Spray

News

NASDAQ.COM

03-23NASDAQ.COM

Milestone Pharmaceuticals Reports Q4 and FY 2025 Results with CARDAMYST Updates

Newsfilter

03-20Newsfilter

Milestone Pharmaceuticals Earnings Report Preview

Yahoo Finance

03-20Yahoo Finance

Milestone Pharmaceuticals Reports Q4 2025 Earnings and CARDAMYST Launch

seekingalpha

03-20seekingalpha

Milestone Pharmaceuticals Reports FY Results

seekingalpha

03-19seekingalpha

Major Earnings Reports Expected on Friday

Newsfilter

01-26Newsfilter

CARDAMYST Nasal Spray Now Available at Retail Pharmacies

3 Analyst Rating

Wall Street analysts forecast MIST stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Wells Fargo

Mohit Bansal

upgrade

$4 -> $8

AI Analysis

2025-12-16

Reason

Wells Fargo

Mohit Bansal

Price Target

$4 -> $8

AI Analysis

2025-12-16

upgrade

Reason

Wells Fargo analyst Mohit Bansal raised the firm's price target on Milestone Pharmaceuticals to $8 from $4 and keeps an Overweight rating on the shares. The firm says Cardamyst's robust label, its reasonable pricing and management's launch strategy bode well for a strong launch. Wells continues to see upside potential to stock despite recent strong performance.

H.C. Wainwright

Brandon Folkes

Buy

upgrade

$5 -> $8

2025-12-15

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$5 -> $8

2025-12-15

upgrade

Buy

Reason

H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Milestone Pharmaceuticals to $8 from $5 and keeps a Buy rating on the shares following the approval of Cardamyst for the treatment of paroxysmal supraventricular tachycardia. The shares at curet levels underappreciate the commercial opportunity of Cardamyst in PSVT, the analyst tells investors in a research note. H.C. Wainwright expects commercial outperformance and the re-initiation of the AFib-RVR trial to drive share momentum over the next 12 to 18 months.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MIST

Unlock Now

Valuation Metrics

The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST.O) is -4.21, compared to its 5-year average forward P/E of -2.82. For a more detailed relative valuation and DCF analysis to assess Milestone Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.82

Current PE

-4.21

Overvalued PE

-1.73

Undervalued PE

-3.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.91

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.91

Undervalued EV/EBITDA

-2.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

47.89

Current PS

5.09

Overvalued PS

140.22

Undervalued PS

-44.44

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most bullish ticker

Intellectia · 46 candidates

Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70

Ticker

Name

Market Cap$

Tarsus Pharmaceuticals Inc

2.78B

Journey Medical Corp

276.86M

Cytokinetics Inc

7.93B

Abcellera Biologics Inc

1.19B

Savara Inc

1.16B

Taysha Gene Therapies Inc

1.29B

undervalued penny stocks rn

Intellectia · 23 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Beta: LowRisk, ModerateRiskWeekly Average Turnover: >= 4,000,000Pe Ttm: <= 8Ps Ratio: <= 0.50

Ticker

Name

Market Cap$

Alight Inc

831.79M

Sellas Life Sciences Group Inc

779.89M

Western Copper and Gold Corp

721.34M

Kosmos Energy Ltd

617.04M

Krispy Kreme Inc

597.84M

Lexinfintech Holdings Ltd

498.06M

Whales Holding MIST

Trading Trends

People Also Watch

Frequently Asked Questions

What is Milestone Pharmaceuticals Inc (MIST) stock price today?

The current price of MIST is 1.01 USD — it has decreased -2.88

What is Milestone Pharmaceuticals Inc (MIST)'s business?

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

What is the price predicton of MIST Stock?

Wall Street analysts forecast MIST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIST is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Milestone Pharmaceuticals Inc (MIST)'s revenue for the last quarter?

Milestone Pharmaceuticals Inc revenue for the last quarter amounts to 1.55M USD, decreased

What is Milestone Pharmaceuticals Inc (MIST)'s earnings per share (EPS) for the last quarter?

Milestone Pharmaceuticals Inc. EPS for the last quarter amounts to -0.16 USD, decreased -15.79

How many employees does Milestone Pharmaceuticals Inc (MIST). have?

Milestone Pharmaceuticals Inc (MIST) has 38 emplpoyees as of March 31 2026.

What is Milestone Pharmaceuticals Inc (MIST) market cap?

Today MIST has the market capitalization of 118.84M USD.